Literature DB >> 29917271

From hepatofibrosis to hepatocarcinogenesis: Higher cytochrome P450 2E1 activity is a potential risk factor.

Jie Gao1, Zhao Wang1, Gao-Ju Wang1, Na Gao1, Jing Li1, Yun-Fei Zhang1,2, Jun Zhou1,3, Hong-Xin Zhang1, Qiang Wen1, Han Jin1, Hai-Ling Qiao1.   

Abstract

Hepatofibrosis is an important susceptibility factor for hepatocarcinogenesis. However, only a handful of cases of hepatofibrosis will develop into hepatocellular carcinoma (HCC). As cytochrome P450 2E1 (CYP2E1) is involved in the metabolism and activation of many known environmental toxicants and procarcinogens, this enzyme may play a role in the development of hepatocarcinogenesis subsequent to hepatofibrosis. Herein, we evaluated whether higher CYP2E1 activity is a risk factor for the development of hepatocarcinogenesis from hepatofibrosis. CYP2E1 activity in fibrotic tissues from 72 HCC patients and in normal liver tissues from 59 control subjects was determined along with the severity of hepatofibrosis in hepatocarcinogenesis patients. Similarly, using a rat diethylnitrosamine-induced hepatocarcinogenesis model, CYP2E1 activity at the hepatofibrosis and hepatocarcinogenesis stages was determined, the correlation between CYP2E1 activity at the hepatofibrosis stage and hepatocarcinogenesis was explored, and the impact of inhibition of CYP2E1 activity on hepatocarcinogenesis was studied. The results showed that while CYP2E1 activity in HCC patients with underlying hepatofibrosis was increased, the severity of hepatofibrosis did not correlate with CYP2E1 activity. In the rat hepatocarcinogenesis model, unexpectedly, CYP2E1 activity was found to decrease from hepatofibrosis to hepatocarcinogenesis. Importantly, however, hepatofibrotic rats with higher CYP2E1 activity developed a more severe form of HCC. Moreover, inhibition of CYP2E1 activity could decrease the occurrence and development of HCC in rats. In conclusion, higher CYP2E1 activity may be a risk factor for hepatocarcinogenesis from hepatofibrosis, which raises the possibility of screening patients with hepatofibrosis for CYP2E1 activity to better estimate their risk for hepatocarcinogenesis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CYP2E1 activity; diethylnitrosamine; hepatic fibrosis; hepatocellular carcinoma; susceptible factor

Mesh:

Substances:

Year:  2018        PMID: 29917271     DOI: 10.1002/mc.22851

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

1.  Effects of Gene Polymorphisms, Metabolic Activity, and Content of Alcohol Dehydrogenase and Acetaldehyde Dehydrogenases on Prognosis of Hepatocellular Carcinoma Patients.

Authors:  Na Gao; Jingjing Chen; Bing Qi; Tianyuan Zhao; Yuanyuan Guo; Yan Fang; Zixinying Han; Hai-Ling Qiao
Journal:  Turk J Gastroenterol       Date:  2022-07       Impact factor: 1.555

2.  Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker.

Authors:  Guiming Hu; Fei Gao; Guanzhe Wang; Yan Fang; Yuanyuan Guo; Jun Zhou; Yuhan Gu; Cunzhen Zhang; Na Gao; Qiang Wen; Hailing Qiao
Journal:  J Transl Med       Date:  2021-08-19       Impact factor: 5.531

3.  The proteomic characterization of the peritumor microenvironment in human hepatocellular carcinoma.

Authors:  Yuhan Gu; Yuanyuan Guo; Na Gao; Yan Fang; Chen Xu; Guiming Hu; Mengxue Guo; Yaxing Ma; Yunfei Zhang; Jun Zhou; Yanlin Luo; Haifeng Zhang; Qiang Wen; Hailing Qiao
Journal:  Oncogene       Date:  2022-03-21       Impact factor: 8.756

4.  Stat4 rs7574865 polymorphism promotes the occurrence and progression of hepatocellular carcinoma via the Stat4/CYP2E1/FGL2 pathway.

Authors:  Caie Wang; Na Gao; Lukui Yang; Yuanyuan Guo; Yan Fang; Tong Wang; Chen Xu; Gui Fang Li; Jun Zhou; Yunfei Zhang; Qiang Wen; Hailing Qiao
Journal:  Cell Death Dis       Date:  2022-02-08       Impact factor: 9.685

5.  The POR rs10954732 polymorphism decreases susceptibility to hepatocellular carcinoma and hepsin as a prognostic biomarker correlated with immune infiltration based on proteomics.

Authors:  Yan Fang; Hongming Yang; Guiming Hu; Jiakun Lu; Jun Zhou; Na Gao; Yuhan Gu; Cunzhen Zhang; Jinhuan Qiu; Yuanyuan Guo; Yunfei Zhang; Qiang Wen; Hailing Qiao
Journal:  J Transl Med       Date:  2022-02-14       Impact factor: 5.531

6.  Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma.

Authors:  Rui Zhang; Wei-Jia Mo; Lan-Shan Huang; Ji-Tian Chen; Wei-Zi Wu; Wei-Ying He; Zhen-Bo Feng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.